Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

However, a recent study from Sunnybrook Research Institute offers some hope. Researchers found that a type of diabetes ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

The findings were alarming. People who took at least one anticholinergic drug had a 47% higher risk of developing memory ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...